No profile data available.
ImmunityBio, Inc. (IBRX) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 684 full-time employees.
It reported revenue of $113.29 million for fiscal year 2025, up 668.3% from fiscal year 2024, and net income of -$351.40 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $51.24 million, up 93.9% from a year before. United States was its largest region in fiscal year 2025, with 100% of revenue. Its market capitalization was $11.14 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
ImmunityBio reported $113.29 million in revenue for fiscal year 2025, up 668.3% from $14.75 million in fiscal year 2024. In Q2 2026 revenue was $51.24 million.
United States: 100% of revenue by region in fiscal year 2025, followed by Europe (under 1%).
$11.14 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Exelixis, Inc. (EXEL), Summit Therapeutics Inc. (SMMT), Halozyme Therapeutics, Inc. (HALO), Iovance Biotherapeutics, Inc. (IOVA).